Biodel Q3 Loss Narrower than Expected, Gives Pipeline Update - Analyst Blog

a generic image of a graph
Credit: Shutterstock photo

Biodel Inc. ( BIOD ), which had incurred a wider-than-expected loss in each of the last two quarters, reported a narrower-than-expected loss in the third quarter of fiscal 2014 report (ended Jun 30, 2014) earlier this week.

Biodel reported a loss of 15 cents per share, narrower than the year-ago loss of 66 cents per share and the Zacks Consensus Estimate of a loss of 26 cents per share.

Biodel Inc - Earnings Surprise | FindTheBest

Biodel did not generate any revenues in the reported quarter and in the year-ago quarter.

Quarter in Detail

Research & development expenses increased 4.4% to $3.6 million. This increase was primarily driven by expenses related to the development of the Glucagon Emergency Management (GEM) product.

General & administrative expenses decreased 23.8% to $1.3 million.

Apart from announcing earnings results, Biodel announced positive results from a phase II study (3-152) on BIOD-531, the company's lead candidate for an ultra-rapid-acting insulin formulation. The company is working with the FDA on the pivotal trial design.

The study demonstrated superiority to Eli Lilly & Company's ( LLY ) Humulin R U-500 and Humalog Mix 75/25 on post prandial glucose control following two standardized meals in patients with type 2 diabetes with moderate insulin resistance.

Meanwhile, Biodel is planning to expand the scope of the study 3-151 on BIOD-531 and it expects to complete the modified study in the fourth quarter of 2014.

The company announced positive results from a human factor study evaluating the successful handling of its GEM device with limited to no training. The final pivotal study is expected to complete in the third quarter of 2015.

Biodel intends to file for a New Drug Application for the device in late 2015.

Biodel carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Endo International plc ( ENDP ) and Avanir Pharmaceuticals, Inc. ( AVNR ). While Endo International carries a Zacks Rank #1 (Strong Buy), Avanir holds a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

BIODEL INC (BIOD): Free Stock Analysis Report

ENDO INTL PLC (ENDP): Free Stock Analysis Report

LILLY ELI & CO (LLY): Free Stock Analysis Report

AVANIR PHARM (AVNR): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More